Through extensive research, experimentation, and clinical trials, experts in the field of drug discovery and development identify promising biopharmaceutical or pharmaceutical drug candidates, optimize their efficacy and safety profiles, and navigate regulatory processes for eventual market approval. From innovative therapies to groundbreaking treatments, this dynamic scientific field plays a pivotal role in revolutionizing medicine and saving lives.
The CORE Library small molecule screening compound stock is a total of more than 600,000 leadlike and druglike small molecule compounds based on novel scaffolds and designs created by ChemBridge. This stock includes 3D, sp3-enriched compounds and grows by approx. 80,000 compounds per year. Customer and custom select from the CORE Library stock.
Structurally diverse pre-plated diversity set with high-scoring chemical features created using compounds from ChemBridge's CORE Library screening compound stock and ChemBridge's EXPRESS-Pick Collection screening compound stock.
Nuclear receptor-directed selection from ChemBridge's CORE Library screening compound stock.
Pre-selected SAR set composed of compounds from ChemBridge's CORE Library screening compound stock.
Ion channel-directed selection from ChemBridge's CORE Library screening compound stock.
Our non-exclusive building block collection, consisting of over 12,000 products, has been developed to support advanced combinatorial lead generation, hit-to-lead, lead optimization and medicinal chemistry programs. The vast majority of our building blocks are not available from any other commercial source listed in ACD.
